Immunotherapy drug shows promise for tough colorectal cancer
NCT ID NCT03981146
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested the immunotherapy drug nivolumab (Opdivo) in 35 adults with advanced colorectal cancer that has a specific marker (class II expression) and is microsatellite stable, a type that usually does not respond to immunotherapy. The goal was to see if the drug could stop the cancer from growing for at least 27 weeks. The study is completed, and results will show whether this approach can help control the disease in patients who have exhausted standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo)
What this could lead to
If successful, this could point toward a new treatment option for people with a hard-to-treat form of colorectal cancer that has not responded to standard therapies.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply to everyone. The cancer type studied is known to be resistant to immunotherapy, so the drug may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Belfast City Hospital
Belfast, United Kingdom
-
Clatterbridge Cancer Centre
Liverpool, United Kingdom
-
Freemans Hospital
Newcastle upon Tyne, United Kingdom
-
Guys Hospital
London, United Kingdom
-
Leicester Royal Infirmary
Leicester, LE1 5WW, United Kingdom
-
Queen Elizabeth Hospital
Birmingham, United Kingdom
-
St James Leeds
Leeds, LS9 7TF, United Kingdom
-
The Christie Hospital, The Christie NHS Foundation Trust
Manchester, United Kingdom
-
The Royal Free Hospital
London, NW3 2QG, United Kingdom
-
The Royal Marsden NHS Foundation Trust
London, United Kingdom
-
University College Hospital
London, United Kingdom
-
Velindre Cancer Centre
Cardiff, United Kingdom
-
Western General Hospital
Edinburgh, United Kingdom
-
Weston Park
Sheffield, S10 2SJ, United Kingdom